Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
saredutant + paroxetine
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Saredutant + paroxetine is an experimental **fixed-dose combination** therapy consisting of saredutant, a neurokinin-2 (NK2) receptor antagonist, and paroxetine, a selective serotonin reuptake inhibitor (SSRI). This combination was investigated in **Phase 3 clinical trials** for **major depressive disorder** (MDD), with the hypothesis that adding saredutant to standard SSRI therapy could improve antidepressant efficacy. Saredutant is designed to modulate neuropeptide signaling pathways implicated in depression and anxiety, while paroxetine is an established antidepressant acting through serotonergic mechanisms[1][2][4][5].
02
Targets
SLC6A1 (Sodium- and chloride-dependent GABA transporter 1)SERT (Sodium-dependent serotonin transporter)GAT2 (Sodium- and chloride-dependent GABA transporter 2)DAT (Dopamine plasma membrane transport protein)GAT-3 (Sodium- and chloride-dependent GABA transporter 3)BGT1 (Betaine/GABA transporter 1)TACR2 (Neurokinin-2 Receptor)NET (Norepinephrine Transporter)
Beyond the preview
Go deeper on saredutant + paroxetine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on saredutant + paroxetine.